Up next

Supplier News: Thermo Fisher, Cambrex, Delpharm & More 

The latest from CDMOs, CMOs, and suppliers featuring Thermo Fisher Scientific, Cambrex, Delpharm, Grand River Aseptic Manufacturing, Famar Group, and Symbiosis.  

Chemicals/Chemical API Manufacturing 
* Cambrex Expands Peptide Mfg Facility 
Formulation Development/Drug Product Manufacturing 
* Thermo Fisher Acquires Fill-Finish Site from Sanofi
* Delpharm Secures Additional Funding for $220-M Injectable Mfg Expansion 
* Famar Group Acquires Sterile Mfg Site From MiP Pharma 
General 
* Thermo Fisher Opens New Center of Excellence for Lab Supplies
Appointments 
* Grand River Aseptic Manufacturing Names New CEO 
* Symbiosis Appoints New Qualified Person

Chemicals/Chemical API Manufacturing 

Cambrex Expands Peptide Mfg Facility 
Cambrex has announced that Snapdragon Chemistry, a Cambrex company, has expanded its active pharmaceutical ingredient (API) facility in Waltham, Massachusetts, to further support the development and manufacturing of peptide therapies. 

The new GMP manufacturing suite increases the overall facility footprint by 20% and includes an ISO-7 cleanroom for preparative HPLC chromatography and lyophilization, cold storage for raw materials, and a product storage suite. With the completion of this investment, Snapdragon can now support peptide projects from development to GMP manufacturing using solid-phase peptide synthesis, liquid-phase peptide synthesis, or hybrid approaches. 

Source: Cambrex 

Formulation Development/Drug Product Manufacturing 

Thermo Fisher Acquires Fill-Finish Site from Sanofi 
Thermo Fisher Scientific has completed its acquisition of Sanofi’s sterile fill–finish and packaging site in Ridgefield, New Jersey.  

Thermo Fisher will continue to manufacture a portfolio of therapies for Sanofi at the Ridgefield site while expanding use of the site to meet demand for US manufacturing capacity. The terms of the deal were not disclosed. The Ridgefield facility is now part of Thermo Fisher’s Pharma Services Business within its Laboratory Products and Biopharma Services Segment. 

Source: Thermo Fisher Scientific 

Delpharm Secures Additional Funding for $220-M Injectable Mfg Expansion 
Delpharm, a CDMO of drug products, has received additional funding of $60 million from the government of Quebec for the expansion of its Boucherville, Quebec, Canada, facility. The site now manufactures 65 million units annually primarily for the Canadian market 

This contribution adds to the previously confirmed $60-million investment from the Canadian federal government, along with $100 million in private capital, bringing the total investment for the expansion to $220 million.The project will expand the plant and install a new sterile filling line. It will also replace 95% of the existing equipment at the facility and increase production capacity for injectable drugs. 

Source: Delpharm 

Famar Group Acquires Sterile Mfg Site From MiP Pharma 
Famar, an Athens, Greece-based CDMO, has completed its acquisition of a sterile production site from MiP Pharma, a Homburg, Germany-based bio/pharmaceutical company, with the transfer of full ownership of the site to Famar. As part of the acquisition, approximately 100 employees are transferred to Famar to ensure continuity and knowledge retention. 

Source: Famar Group

General 

Thermo Fisher Opens New Center of Excellence for Lab Supplies 
Thermo Fisher Scientific has announced the opening of an Innovative Manufacturing Center of Excellence for laboratory pipettes in Mebane, North Carolina. The new 375,000-square-foot site will be capable of producing at least 40 million laboratory pipette tips per week. 

The site results from a $192.5-million contract, in coordination with the US Department of Health and Human Services and the US Department of Defense, awarded in 2021.  

Source: Thermo Fisher Scientific 

Appointments 

Grand River Aseptic Manufacturing Names New CEO 
Grand River Aseptic Manufacturing (GRAM), a CDMO of sterile manufacturing services, has announced the promotion of Denis Johnson, current President of GRAM, to Chief Executive Officer, effective September 1, 2025. Johnson has served as President of GRAM since March 31, 2025. He will succeed Derek Hennecke, who served as CEO since September 15, 2024, and will return to GRAM’s Board of Directors. 

Johnson brings extensive life sciences leadership and manufacturing experience to this role, including prior sterile fill-finish experience. His prior roles include Head of Global Manufacturing and Technical Operations at Biogen as well as leadership roles at Catalent, Boston Scientific, and Johnson & Johnson. He started his career in the US Army managing logistics and operations. 

Source: Grand River Aseptic Manufacturing 

Symbiosis Appoints New Qualified Person 
Symbiosis, a CDMO of sterile fill–finish services, has announced the appointment of Wendy Cook as a Qualified Person (QP) as part of the company’s regulatory and quality leadership team. Cook brings more than 20 years of pharmaceutical quality assurance experience across GLP, GCP and GMP environments, with experience in sterile manufacturing and clinical trial supply chains. Since qualifying as a QP in 2018, she has held roles at both CDMOs and global CMOs, where she oversaw batch certification, regulatory submissions and quality oversight across multiple dosage forms, including sterile injectables. 

Source: Symbiosis